KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Change in Acquisitions & Divestments (2016 - 2025)

Eli Lilly filings provide 17 years of Change in Acquisitions & Divestments readings, the most recent being $132.0 million for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 135.71% to $132.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $964.0 million, a 157.75% increase, with the full-year FY2025 number at $964.0 million, up 157.75% from a year prior.
  • Change in Acquisitions & Divestments hit $132.0 million in Q4 2025 for Eli Lilly, down from $556.1 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $753.4 million in Q4 2021 to a low of -$172.3 million in Q2 2023.
  • Median Change in Acquisitions & Divestments over the past 5 years was $69.2 million (2024), compared with a mean of $149.4 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: soared 6811.93% in 2021 and later tumbled 657.61% in 2023.
  • Eli Lilly's Change in Acquisitions & Divestments stood at $753.4 million in 2021, then crashed by 65.61% to $259.1 million in 2022, then soared by 36.16% to $352.8 million in 2023, then tumbled by 84.13% to $56.0 million in 2024, then skyrocketed by 135.71% to $132.0 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $132.0 million (Q4 2025), $556.1 million (Q3 2025), and $204.3 million (Q2 2025) per Business Quant data.